Serum interferon-gamma is a psoriasis severity and prognostic marker

Area of Science:

• Immunodermatology
• Biochemistry

Background:

• Psoriasis is a chronic inflammatory skin disease.
• Interferon-gamma (IFN-gamma) is a cytokine implicated in immune responses.
• The role of IFN-gamma in psoriasis pathogenesis and its correlation with disease severity require further elucidation.

Purpose of the Study:

• To measure serum IFN-gamma levels in patients with different types and severities of psoriasis.
• To investigate the correlation between serum IFN-gamma levels and psoriasis severity (PASI scores).
• To assess the change in serum IFN-gamma levels in response to treatment and its impact on disease remission.

Main Methods:

• Serum IFN-gamma levels were measured using enzyme-linked immunosorbent assay (ELISA) in 21 psoriasis patients and matched controls.
• Patients were categorized into erythrodermic, severe plaque, and mild to moderate plaque psoriasis groups.
• IFN-gamma levels were analyzed before and after 16 weeks of treatment, with a subsequent 12-week follow-up.

Main Results:

• Significantly higher serum IFN-gamma levels were observed in psoriasis patients compared to controls (P<.05).
• A positive correlation was found between serum IFN-gamma levels and Psoriasis Area and Severity Index (PASI) scores, with highest levels in erythrodermic psoriasis.
• A significant decrease in serum IFN-gamma levels was associated with clinical improvement (decreased PASI) and longer remission periods in 13 of 15 treated patients.

Conclusions:

• Serum IFN-gamma levels are elevated in psoriasis and vary with disease severity.
• IFN-gamma levels serve as a potential biomarker for evaluating psoriasis disease severity and treatment response.
• Further research into anti-IFN-gamma biologic therapies for psoriasis is warranted.